Pharma Mar : Newsflow drought ahead
>Zepzelca brought peace of mind… - Following two major setbacks in 2017-2018 (Zepsyre and Aplidin), Pharma Mar got back on track in 2019-2020 with (conditional) FDA approval for Zepzelca (2L SCLC) and the agreement with Jazz to market it in the US. This agreement helped them compensate for the Yondelis generic cliff and generate enough revenue to cover R&D and generate some cash not to mention its comfortable € 0.2bn milestone-built net cash position. …bu...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.